<DOC>
	<DOC>NCT01104675</DOC>
	<brief_summary>The purpose of this study is to determine whether oral ENMD-2076 is effective in treatment of patients with platinum resistant ovarian, fallopian, or peritoneal cancer. Additional sites to be added.</brief_summary>
	<brief_title>Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Have histologically documented diagnosis of ovarian, fallopian or peritoneal cancer that is platinum resistant. Have a prestudy echocardiogram or multigated acquisition (MUGA) scan with an actual left ventricular ejection fraction of greater than or equal to the institution lower limit of normal Greater than or equal to 18 years of age Have clinically acceptable laboratory screening results Have an ECOG performance status of 0 or 1 Able to tolerate oral medications Have uncontrolled hypertension (systolic blood pressure greater than 150mmHg or diastolic blood pressure greater than 100mmHg); require two or more antihypertensive medications to control hypertension (including ACE inhibitors, beta blockers, calcium channel blockers, or diuretics) Have chronic atrial fibrillation or QTc interval corrected for heart rate of greater than 470 msec Have active, acute, or chronic clinically significant infections or bleeding Have persistent 2+ protein by urinalysis or a history of nephrotic syndrome</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>ovarian</keyword>
	<keyword>platinum resistant ovarian cancer</keyword>
</DOC>